UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy

Inflammatory bowel diseases, 2013-09, Vol.19 (10), p.2111-2117

2013

Link zum Volltext

Verfügbarkeit prüfen

Preference for a prefilled syringe or an autoinjection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study.(ORIGINAL RESEARCH)(Clinical report)

Patient preference and adherence, 2018-01, Vol.12, p.1193

2018

Link zum Volltext

Verfügbarkeit prüfen

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study

Patient preference and adherence, 2018-01, Vol.12, p.1193-1202

2018

Link zum Volltext

Verfügbarkeit prüfen

COVID‐19 and digestive health: Implications for prevention, care and the use of COVID‐19 vaccines in vulnerable patients

United European gastroenterology journal, 2021-11, Vol.9 (9), p.1091-1095

2021

Link zum Volltext

Verfügbarkeit prüfen

Is Crohn’s Disease a Rightly Used Eponym?

Journal of Crohn's and colitis, 2020-07, Vol.14 (6), p.867-871

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study

Journal of Crohn's and colitis, 2019-10, Vol.13 (11), p.1401-1409

2019

Link zum Volltext

Verfügbarkeit prüfen

W1194 Impact of an Extensive Thiopurine Methyltransferase (TPMT) Genotyping in Inflammatory Bowel Disease Patients Who Experienced Myelosuppression During Antipurine Therapy

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-671-S-671

2010

Link zum Volltext

Verfügbarkeit prüfen

In Memoriam: Emeritus Prof. Dr. Paul Rutgeerts (1948–2020)

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (6), p.1543-1545

2022

Link zum Volltext

Verfügbarkeit prüfen

Mo1558: REAL-WORLD EFFECTIVENESS AND SAFETY OF RISANKIZUMAB FOR MODERATE-SEVERE MULTI-REFRACTORY CROHN’S DISEASE: RESULTS FROM A BELGIAN MULTI-CENTRIC COHORT

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-818-S-819

2022

Link zum Volltext

Verfügbarkeit prüfen

Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial

Clinical gastroenterology and hepatology, 2022-09, Vol.20 (9), p.2074-2082

2022

Link zum Volltext

Verfügbarkeit prüfen

Endoscopic removal of an extraluminal, intrapancreatic dislocated common bile duct stone

Endoscopy, 2020-02, Vol.52 (2), p.E59

2020

Link zum Volltext

Verfügbarkeit prüfen

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Inflammatory bowel diseases, 2019-01, Vol.25 (1), p.156-162

2019

Link zum Volltext

Verfügbarkeit prüfen

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

The lancet. Gastroenterology & hepatology, 2023-03, Vol.8 (3), p.215-227

2023

Link zum Volltext

Verfügbarkeit prüfen

Jejuno-ileal diverticulosis : a review of literature

Acta gastro-enterologica belgica, 2018-10, Vol.81 (4), p.517-519

2018

Link zum Volltext

Verfügbarkeit prüfen

Mo1847 - Reactive Dose Escalation of Infliximab in Patients with Crohn's Disease in Tailorix Leads to Improved Outcomes

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-823-S-824

2018

Link zum Volltext

Verfügbarkeit prüfen

946 DEEP REMISSION AT 1 YEAR IS NOT ASSOCIATED WITH BETTER OUTCOME IN CROHN'S DISEASE: LONG-TERM DATA FROM TAILORIX

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-192-S-192

2020

Link zum Volltext

Verfügbarkeit prüfen

Tu1895 TOFACITINIB INDUCES CLINICAL AND ENDOSCOPIC REMISSION IN BIOLOGIC REFRACTORY ULCERATIVE COLITIS PATIENTS: A REAL-WORLD BELGIUM COHORT STUDY

Gastroenterology (New York, N.Y. 1943), 2020-05, Vol.158 (6), p.S-1208-S-1208

2020

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 and digestive health

United European gastroenterology journal, 2020-06, Vol.8 (5), p.624-626

2020

Link zum Volltext

Verfügbarkeit prüfen

Mo1910 – Long-Term Clinical Efficacy of Ustekinumab in Refractory Crohn’s Disease: A Multi-Centre Belgian Cohort Study

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-882-S-883

2019

Link zum Volltext

Verfügbarkeit prüfen

Mo1865 - Ustekinumab Induces Clinical and Biological Remission in Biologic Refractory Crohn's Disease Patients: A Real World Belgian Cohort Study

Gastroenterology (New York, N.Y. 1943), 2018-05, Vol.154 (6), p.S-830-S-831

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response

GastroHep, 2021-03, Vol.3 (2), p.63-71

2021

Link zum Volltext

Verfügbarkeit prüfen

692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX)

Gastroenterology (New York, N.Y. 1943), 2016-04, Vol.150 (4), p.S143-S143

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Gastroenterology & Hepatology
(19)
Humans
(16)
Female
(10)
Gastroentérologie & Hépatologie
(10)
Human Health Sciences
(10)
Sciences De La Santé Humaine
(10)
Male
(9)
Adult
(8)
Crohn's Disease
(6)
Infliximab
(6)
Middle Aged
(6)
Treatment Outcome
(6)
Antibodies, Monoclonal - Therapeutic Use
(5)
Crohn Disease - Drug Therapy
(5)
Remission Induction
(5)
Ulcerative Colitis
(5)
Young Adult
(5)
Life Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy

Preference for a prefilled syringe or an autoinjection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study.(ORIGINAL RESEARCH)(Clinical report)

Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study

COVID‐19 and digestive health: Implications for prevention, care and the use of COVID‐19 vaccines in vulnerable patients

Is Crohn’s Disease a Rightly Used Eponym?

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study

W1194 Impact of an Extensive Thiopurine Methyltransferase (TPMT) Genotyping in Inflammatory Bowel Disease Patients Who Experienced Myelosuppression During Antipurine Therapy

In Memoriam: Emeritus Prof. Dr. Paul Rutgeerts (1948–2020)

Mo1558: REAL-WORLD EFFECTIVENESS AND SAFETY OF RISANKIZUMAB FOR MODERATE-SEVERE MULTI-REFRACTORY CROHN’S DISEASE: RESULTS FROM A BELGIAN MULTI-CENTRIC COHORT

Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial

Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease

Endoscopic removal of an extraluminal, intrapancreatic dislocated common bile duct stone

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Jejuno-ileal diverticulosis : a review of literature

Mo1847 - Reactive Dose Escalation of Infliximab in Patients with Crohn's Disease in Tailorix Leads to Improved Outcomes

946 DEEP REMISSION AT 1 YEAR IS NOT ASSOCIATED WITH BETTER OUTCOME IN CROHN'S DISEASE: LONG-TERM DATA FROM TAILORIX

Tu1895 TOFACITINIB INDUCES CLINICAL AND ENDOSCOPIC REMISSION IN BIOLOGIC REFRACTORY ULCERATIVE COLITIS PATIENTS: A REAL-WORLD BELGIUM COHORT STUDY

COVID-19 and digestive health

Mo1910 – Long-Term Clinical Efficacy of Ustekinumab in Refractory Crohn’s Disease: A Multi-Centre Belgian Cohort Study

Mo1865 - Ustekinumab Induces Clinical and Biological Remission in Biologic Refractory Crohn's Disease Patients: A Real World Belgian Cohort Study

Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response

692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX)

Suchergebnisse filtern